Scans Reveal What The Brains of Psychopaths Have in Common
Led by researchers from the Research Center Jülich and RWTH Aachen University in Germany, the study compared brain scans of men diagnosed as psychopaths against brain scans from male volunteers without the condition.
"Psychopathy is one of the greatest risk factors for serious and persistent violence," write the researchers in their published paper.
"In order to detect its neurobiological substrates, we examined 39 male psychopathic subjects and matched controls using structural magnetic resonance imaging and the Psychopathy Check-List (PCL-R)."
Related:
The PCL-R combines interview results with professional assessments and official records to produce three scores: an overall score, a factor 1 score that measures interpersonal and emotional traits, and a factor 2 score that measures impulsive and antisocial behavior.
While there were only slight differences in brain structure corresponding to factor 1 scores, when it came to factor 2, the researchers found significant reductions in certain brain regions among people who scored highly – including in the pons part of the brainstem, the thalamus, the basal ganglia, and the insular cortex.
Research has shown these regions mediate control over involuntary actions, and are linked to emotional processing, interpreting sensory information, motivation, and decision making. In other words, these functions play a critical role in determining how we react to our environment.
What's more, the brains of psychopathic subjects were found to be around 1.45 percent smaller than those of control subjects, on average. This is tricky to interpret, but might point to developmental problems in people classed as psychopaths.
"The present results suggest that the behavioral disturbances that are captured by the PCL-R factor 2 are associated with volume deficits in regions which belong to frontal-subcortical circuits that could be involved in behavioral control," write the researchers.
This is a relatively small-scale study with limited diversity of subjects, so further research will be needed to gather more data. The results imply antisocial and impulsive behaviors in those with psychopathic personalities could be heavily influenced by shared neurological characteristics.
Future studies may also consider other possible reasons for these differences in brain structure – which could include drug abuse, for example, or traumatic experiences – to help identify cause and effect more clearly.
The debate continues about exactly how to classify psychopathy, which typically manifests itself as a chronic lack of empathy, manipulative behavior, and a tendency to be impulsive and take risks.
Although the level of psychopathy can vary from person to person, it can also lead to aggressive and violent actions, as the researchers behind this latest study point out – and with a better understanding of the condition, that might be something we can change.
"In conclusion, these findings are compatible with the dimensionality of the PCL-R construct, and suggest a particularly strong association of antisocial behavior to smaller volumes in widespread subcortical-cortical brain regions," write the researchers.
The research has been published in the European Archives of Psychiatry and Clinical Neuroscience.
First Step Towards an Artificial Human Genome Now Underway
Nightmares Could Make You 3 Times More Likely Die Before 75
The Secret to Better Sleep Could Be As Simple As Eating More Fruit And Veggies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
13 hours ago
- Medscape
PCPs Guide to Prescribing Blood Thinners for AF
As a primary care physician (PCP), you're often the first healthcare professional that will identify cardiac issues, including atrial fibrillation (AF). Individuals with AF face a fivefold risk for stroke. Therefore, these patients are often prescribed blood-thinning medications (anticoagulants) to slow blood clotting, according to the American Society of Hematology (ASH). Up to six million Americans have AF, the risk for which increases with age. The ASH says there are 450,000 hospitalizations each year because of AF. It's very important to check on your patient's response within the first few months of taking blood thinners. In fact, patients with AF who took low doses of oral anticoagulants experienced a higher incidence of bleeding episodes during the first 3 months of treatment, according to a study published in Blood Advances . When Should PCPs Prescribe Anticoagulants? PCPs should consider prescribing oral anticoagulants when they are the principal caregivers for patients with AF, acute deep venous thrombosis, or acute pulmonary embolism, according to R. Michael Benitez, MD, a cardiologist at the University of Maryland Medical Center and a professor of medicine in the Division of Cardiovascular Medicine at the University of Maryland School of Medicine in Baltimore. The decision to prescribe an oral anticoagulant must be based upon the patient's risk without anticoagulation weighed in context with the patient's risk for significant bleeding, he said. How Can Physicians Best Communicate the Rationale for Anticoagulant Therapy? When describing AF, PCPs can explain to patients that the upper chamber of heart is 'wiggling' and not effectively contracting and when blood is not being effectively moved forward, it tends to clot, said Benitez. Physicians can also share that a clot as small as 2 mm is large enough to cause a major stroke if it were to break loose from the inside of the top chamber and be pumped with the blood to the brain, suggested the cardiologist. 'The oral anticoagulant greatly reduces the risk of the formation of these blood clots and subsequent stroke,' Benitez said. 'Stroke is a terrible event that, if survived, often changes a patient's life permanently and significantly. In the setting of atrial fibrillation, anticoagulation greatly reduces the patient's risk of stroke.' Regarding deep venous thrombosis, physicians can explain that a blood clot in the leg veins could break loose and be pumped through the right side of the heart to the lungs. 'This event, pulmonary embolism, can cause critical illness or even death; the risk can be greatly reduced through the use of oral anticoagulants,' said Benitez. What Are Important Directives Regarding Usage? PCPs should stress that daily use is critical to the success of the drug in preventing stroke. 'In the case of the new direct oral anticoagulants, such as apixaban or rivaroxaban, the drugs both work very quickly but also wear off very quickly,' said Benitez. 'This means that even missing just 2-3 days is enough for the blood to again clot normally. It is essential that the drugs be taken daily to prevent stroke.' In the case of warfarin, the effect of the drug is more prolonged. While missing a single dose is unlikely to markedly change the degree of anticoagulation, it's still best to remind patients not to miss doses and take this daily as prescribed, according to Benitez. What Side Effects Should Be Discussed? It is extremely important with warfarin — and to a lesser degree with direct oral anticoagulants — to always make certain that there is no drug-drug interaction that might affect the degree of anticoagulation when new medications are introduced, such as antibiotics, said Benitez. Other side effects to bring to a patients' attention are minor bleeding (such as gum bleeding with dental flossing) or nose bleeds that stop easily, which don't require immediate medical attention. However, your patients should self-monitor bleeding episodes and know a course of action if injured. 'If bleeding will not readily stop then medical attention is needed, and patients who incur major injury or trauma are likely to be taken to an emergency facility where it is important for the staff caring for them to know what anticoagulant they are taking, the dose, and when they last took it,' Benitez said. 'Reversal agents are now available to normalize blood clotting.' Your patients may be concerned with food that could interact with these medications. Benitez said there are no significant food interactions or dietary restrictions. But when prescribing warfarin, some nutritional guidance is warranted. 'With warfarin, which is a vitamin K antagonist, it is essential that the patient limit their intake of food containing vitamin K, as it is essentially an antidote or reversal agent for the anticoagulant,' he said. Some sources of vitamin K are well-known, such as leafy vegetables like spinach, kale, and other greens. However, there are many other dietary sources rich in vitamin K that may not be as obvious, such as cauliflower and soy products, Benitez said. 'It is important for the patient to familiarize themselves with vitamin K-containing foods and to keep the intake of them low and steady from day to day if they are taking warfarin,' he said.
Forbes
21 hours ago
- Forbes
Matching Occupational Exoskeletons With The Right Work Task
Regardless of whether one thinks of industrial exoskeletons as personal protective equipment (PPE), an engineering solution, or something in between, these wearable devices are still an ergonomic solution that needs to be applied to the correct problem. In the decade that this technology has started to see an ever-growing adoption at work sites, the responsibility of matching the exoskeleton with a job task continues to fall on the end user or buyer. This is a persistent hurdle towards mass adoption, with several solutions on the horizon. How it started: Like any new technology, exoskeleton startups had no choice but to sell their products directly. This meant that if a company wanted to select and compare devices, it had to discover each one and establish unique communication channels. This process can be slow and laborious, and the lessons learned by one buyer are often not shared with others. One exception that exists in the public domain is 'The implementation of cobotics and exoskeletal devices for the Australia red meat processing industry,' a 91-page report published by AMPC comparing 19 industrial exoskeletons. Ten years later, the landscape has gone through some dramatic changes. Multiple standards bodies have looked into classifying and evaluating occupational exoskeletons. Fraunhofer IPA, a leading German research institute, has created a series of parcours to evaluate occupational exoskeletons as product families grouping results by task. Another change is the emergence of distributors, which could either be dedicated to one supplier or carry multiple products from different developers. As a quick note, choosing the correct exoskeleton solution (or deciding if a wearable is even the correct solution) for a repetitive work task is just one piece of the puzzle for a successful implementation. Still, it is often the first step in the process, and an error there will cascade down through pilots and long-term adoption efforts (and will most certainly negatively impact any return business). Even with all these changes, the majority of occupational exoskeletons are still sold directly by their producers, with some alternative acquisition and comparison pathways emerging: First, several dedicated consulting companies have sprouted in North America and Europe, which can provide support in choosing the right exoskeleton system for a fee. Second, some distributors carry devices from multiple developers, and their sales team is becoming more experienced with the strengths of each one. Third, some companies go beyond the role of a distributor and have become closer to an integrator that goes on a journey with the end user and buyers, helping them through the entire process of selection, comparison, and setting up a pilot. Last but not least, in the age of AI and digital tools, there have been multiple systems proposed that can collect data from repetitive work tasks, and some are designed specifically for wearables. The challenge with this digital solution is data collection, which can range from cell phone videos to motion tracking or even full EMG studies, but that is not all, because in addition to data collection, data interpretation with these systems is not trivial and requires effort before it can be condensed and summarized into a digestible report. How could things shape up in the future? There are a few likely scenarios on how the complexity of selecting an occupational exoskeleton could be reduced while creating a more positive and streamlined experience for decision makers and buyers. The car dealership route - developers of occupational exoskeletons could continue to consolidate so that each one has a full portfolio. This would be similar to shopping for a car, where car company A would offer sedans through trucks and everything in between, and the dealership next to it would offer the same range of vehicle classes from a different maker. An alternative to that would be an increase in multi-vendor distributors that already carry competing brands. Some examples of this happening right now would be Stanley Handling and FoxInnovation in Europe, The Exoskeleton Store and ExxoVantage in the Americas and Oceania. With this model, buyers have to visit fewer places and can also leverage the experience of the multi-vendor distributors to assist with selection. The final version could be an investment and improvement in digital tools. This could include online comparison tools, such as those found on car or camera equipment websites, or something more custom that can collect and interpret data from job sites and compare it against the known capabilities of different types and brands of industrial exoskeletons. All this work will lead to the formation of a marketplace, allowing buyers and end users to compare and evaluate industrial wearable solutions against data or prior knowledge. This would simplify the buying process considerably and lower the entry barrier for professionals and companies interested in becoming early adopters of wearable devices that provide direct physical support for their jobs.
Yahoo
a day ago
- Yahoo
Immunophotonics Completes Treatment of Last Patient in INJECTABL-1 Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors
IP-001, Immunophotonics' proprietary glycan polymer, is designed to transform tumor ablation into personalized systemic cancer immunotherapies ST. LOUIS, July 31, 2025 /PRNewswire/ -- Immunophotonics, Inc., a clinical-stage biotech company developing novel immunostimulatory drugs to improve efficacy of routine tumor destruction techniques, has announced the completion of treatment of the last patient in its INJECTABL-1 multicenter Phase 1b/2a clinical trial of IP-001 for advanced solid tumors. The 41-patient trial, which focused on three distinct cancer types — colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma— was conducted in France, Germany, Switzerland, the UK, and the US. The INJECTABL-1 trial was designed to evaluate the systemic immune-mediated anti-cancer effects of IP-001 following tumor ablation, which aims to destroy all cells in targeted tumor lesions in patients with advanced solid tumors but fails to induce robust anti-tumor immunity. Tumor ablation is an approved and well-established procedure that is readily available at most hospitals and clinics. IP-001 is a novel immunotherapy administered by injection into the ablation zone. It works by retaining tumor debris, including tumor antigens, and by activating the patient's own immune system to allow systemic tumor surveillance. Such immune surveillance enables the patient's own defense mechanisms to recognize and destroy tumor cells that had escaped the destroyed metastatic lesion. Prof. Dr. Markus Jörger, Principal Investigator for the trial at the Cantonal Hospital St. Gallen Clinic for Medical Oncology and Hematology, commented: "We are proud to announce the completion of treatment of the last patient in our INJECTABL-1 Phase 1b/2a clinical trial. This significant milestone brings us closer to potentially providing a new treatment option for patients with advanced solid tumors." "Immunophotonics is committed to leading the field of Interventional Immuno-Oncology® through a therapeutic approach intended to reduce tumor recurrence after standard-of-care local ablation therapy, which remains a significant unmet medical need. With the completion of our INJECTABL-1 trial, we will evaluate data to assess IP-001's ability to transform ablation into something more powerful as we continue to advance the clinical development of our proprietary novel asset. Early signals are positive, and the company has expanded clinical collaborations to further assess the efficacy of this novel therapy," stated Lu Alleruzzo, Immunophotonics co-founder and CEO. About IP-001IP-001 is a proprietary glycan polymer that generates tumor antigen depots and acts as a potent, multimodal immune stimulant intended to induce immunological responses to eradicate cancer. IP-001 is designed to (1) prolong the availability of the targeted tumor antigens, (2) facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) lead to a downstream adaptive immune response against the tumor cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumor cells throughout the body. About ImmunophotonicsImmunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology®. IP-001, which is the first asset from the company's intellectual property platform and is currently assessed in multiple clinical trials, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific immune response in solid cancers. By combining routine energy therapies, such as ablation or radiation, with injection of its proprietary immunoadjuvant (IP-001), Immunophotonics aims to trigger a systemically active anti-cancer immune response that can destroy circulating tumor cells and micrometastases left behind after ablation. The company's world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland. For more information, visit Cautionary Note Regarding Forward-Looking StatementsThis press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law. Investor Contacts:Tiberend Strategic Advisors, Nugentjnugent@ orDavid Irishdirish@ View original content to download multimedia: SOURCE Immunophotonics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
